Company intelligence / Profile preview

Antares Pharma, Inc.

Ewing, New Jersey, United States of Americahalozyme.com ↗

Ownership: Private
Employees: ~201
Development stage: Commercial

Overview

Antares Pharma develops and commercializes pharmaceutical products using proprietary drug delivery systems, with a focus on self-administered parenteral products. Their commercial products include XYOSTED (testosterone enanthate) injection, OTREXUP (methotrexate) injection, NOCDURNA (desmopressin acetate), Epinephrine Injection USP, Sumatriptan Injection USP, Makena Subcutaneous Auto Injector, and Teriparatide Injection.

Therapeutic areas: Men's HealthNephrologyRheumatologyEndocrinologyNeurology
Modalities: Self-injection technologiesDrug delivery systemsSubcutaneous injection technology
Industry: Biotech

Drug pipeline

1 asset

Xyosted

Commercial

Indications: Male health diseases

Partnerships

Teva Pharmaceutical Industries LtdFerring PharmaceuticalsAMAG

Beyond the preview

Go deeper on Antares Pharma, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Antares Pharma, Inc..

Explore the full profile